Comparative Pharmacology
Head-to-head clinical analysis: ENSKYCE versus LEVONEST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENSKYCE versus LEVONEST.
ENSKYCE vs LEVONEST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ENSKYCE (fospropofol disodium) is a prodrug of propofol. It is hydrolyzed by alkaline phosphatases to release propofol, which acts as a positive allosteric modulator of GABA-A receptors, enhancing chloride conductance and producing sedation and anesthesia.
Levonorgestrel is a synthetic progestin that inhibits ovulation by suppressing luteinizing hormone (LH) surge, alters cervical mucus to impede sperm penetration, and induces endometrial changes that inhibit implantation.
2 g IV every 8 hours over 5 hours on days 1-3 of each 21-day cycle
One tablet (levonorgestrel 1.5 mg) orally as a single dose within 72 hours of unprotected intercourse.
None Documented
None Documented
12 hours (terminal); allows once-daily dosing in most patients
The terminal elimination half-life is approximately 24-30 hours. This relatively long half-life supports once-daily dosing and allows for stable plasma concentrations within 5-7 days of continuous use.
Renal: ~70% unchanged; Biliary/Fecal: ~20% as metabolites
Renal excretion of conjugated metabolites accounts for approximately 60-80% of an administered dose; fecal elimination via bile accounts for 20-40%.
Category C
Category C
Oral Contraceptive
Oral Contraceptive